CardioFocus — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

CardioFocus is a private medical device company specializing in pulsed field ablation systems for the treatment of atrial fibrillation. Its core strategy is the integrated co-engineering of catheters and generators, focusing on waveform science and contact mechanics to achieve precise lesion formation. The company's pipeline features two investigational devices: the QuickShot™ Nav focal catheter and the OptiShot™ balloon catheter, both aimed at improving procedural efficiency and outcomes in electrophysiology. CardioFocus operates in the rapidly expanding cardiac ablation market, competing against established players with a science-led, system-level approach.

CardiovascularAtrial Fibrillation

Technology Platform

Integrated pulsed field ablation (PFA) ecosystem co-engineering proprietary waveform science with catheter design and contact mechanics for precise, efficient cardiac tissue electroporation.

Opportunities

The global shift towards pulsed field ablation for atrial fibrillation creates a multi-billion dollar, high-growth market.

CardioFocus's integrated system-level approach and versatile catheter portfolio could capture share by demonstrating superior lesion durability and procedural efficiency.

The platform's design for multiple ablation strategies also addresses the growing need for treating persistent AF beyond simple pulmonary vein isolation.

Risk Factors

CardioFocus faces intense competition from large, established medtech companies with first-mover advantage in PFA.

As an investigational-stage company, it carries significant regulatory and clinical trial execution risk.

Successful market penetration post-approval will require substantial commercial investment against competitors with entrenched sales forces and physician relationships.

Competitive Landscape

The PFA market is highly competitive, dominated by large players like Medtronic (PulseSelect), Boston Scientific (FARAPULSE), and Johnson & Johnson (VARIPULSE). These competitors have commercial products, extensive clinical data, and global commercial infrastructure. CardioFocus differentiates through its deep waveform science and integrated catheter-generator design, but must prove clinical superiority to overcome the incumbents' market lead.

More companies in Digital Health & Biotech SaaS →More companies in United States →